BioSpace News Archive

Cancer cells use a bizarre strategy to reproduce in a tumor’s low-energy environment; they mutilate their own mitochondria! Researchers at Cold Spring Harbor Laboratory (CSHL) also know how this occurs, offering a promising new target for pancreatic cancer therapies.

“I wanted a more convenient way to relieve tinnitus that did not require invasive procedures,” said an inventor from Encinitas, Calif. “I came up with this idea so that people could achieve relief from tinnitus in a comfortable and convenient manner.”

Gov. Roy Cooper last week signed a bill amending North Carolina’s Drug Depository Program to broaden the availability of donated prescription drugs and allow free clinics to better serve people who are uninsured and underinsured.

Merz North America, Inc. and Cytophil, Inc. announced that they have reached an agreement settling all claims between them.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Company has been added as a member of the Russell 2000® and Russell 3000® Indexes effective at the opening of trading today, July 1, 2019.

Brodies LLP, Scotland’s largest law firm, has appointed high-growth specialist, David Gallagher as partner in its commercial services team.

Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces the appointment of Dr Steven Chatfield to its Scientific Advisory Board (SAB).

DotLab, a personalized medicine company for women’s health, announced today that it has secured $10 million in Series A funding.

Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors that incorporates multiple companion diagnostics.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington, Ph.D. to its Board of Directors, effective June 27, 2019.